Therapeutics

Sangamo Therapeutics Pronounces Transition to Buying and selling on OTCQB Enterprise Market
Stock Market

Sangamo Therapeutics Pronounces Transition to Buying and selling on OTCQB Enterprise Market

Antag Therapeutics to current knowledge on AT7687, its first-in-class GIPR antagonist peptide on the American Diabetes Affiliation’s 2026 Scientific Periods
Press Releases

Antag Therapeutics to current knowledge on AT7687, its first-in-class GIPR antagonist peptide on the American Diabetes Affiliation’s 2026 Scientific Periods

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Soleno Therapeutics, Inc. Buyers to Safe Counsel Earlier than Vital Deadline in Securities Class Motion – SLNO
Company Announcement

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Soleno Therapeutics, Inc. Buyers to Safe Counsel Earlier than Vital Deadline in Securities Class Motion – SLNO

Lyra Therapeutics, Inc. Proclaims Intention to Voluntarily File Kind 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
Stock Market

Lyra Therapeutics, Inc. Proclaims Intention to Voluntarily File Kind 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC

Kailera Therapeutics Pronounces Pricing of Preliminary Public Providing
Stock Market

Kailera Therapeutics Pronounces Pricing of Preliminary Public Providing

Vivoryon Therapeutics N.V. to Report Full 12 months 2025 Monetary Outcomes and Enterprise Updates on April 23, 2026
Company Announcement

Vivoryon Therapeutics N.V. to Report Full 12 months 2025 Monetary Outcomes and Enterprise Updates on April 23, 2026

Allogene Therapeutics Proclaims Proposed Public Providing of 5 Million of Frequent Inventory
Stock Market

Allogene Therapeutics Proclaims Proposed Public Providing of $175 Million of Frequent Inventory

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Place with AI-Pushed Tech in Automated Compliance Area
Featured Article

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Place with AI-Pushed Tech in Automated Compliance Area

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Traders With Losses Could Search to Lead the Class Motion After Allegedly Deceptive Institutional Shareholders: Levi & Korsinsky
Company Announcement

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Traders With Losses Could Search to Lead the Class Motion After Allegedly Deceptive Institutional Shareholders: Levi & Korsinsky

Denali Therapeutics Regains Full Rights to Investigational Remedy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Partnerships

Denali Therapeutics Regains Full Rights to Investigational Remedy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)